Bullpen

🔥Just announced🔥Orange County Bio (OC Bio) will be sponsoring Phacilitate’s Advanced Therapies Awards Jan 22nd in Dallas, Tx. 📬Entries opened July 17th and close September 27 Apply here: https://lnkd.in/gvdibG2W 💪 If you don't know OC Bio...Justin Smith and Dominic Clarke are taking C&GT sales and marketing to the next level 🚀 😎 I am a judge this year. My job is to make it fun and spread the word. I got this! Everyone has an amazing teammate to honor right? 😘 The Advanced Therapies Awards recognize and celebrate progress in the advanced therapies field. The celebration will include a themed gala dinner as part of Advanced Therapies Week in Dallas. The evening will bring together the advanced therapies community to network and celebrate each other’s successes. 📣Hoping to get nominations flowing with a little help from Bullpen Member C&GT leaders: Marty Giedlin, PhD, Raphaël G. Ognar, MSc MBA, Jason Cordeiro, Priya Baraniak, Ph.D., Stella K. Vnook, Tari Suprapto, Caley Anderson, MBA, Anna (Haugo) Argo, MBA, Mike Davies, MD, FRCS, Robert Boyce, Russell Carrington, Don Davis PhD, MBA, George Eastwood, Laura Hameed, Elaine H., Nikhil Joshi, Jeff Milton, Ben Noren, Julia Taravella 👨⚖️ Looking forward to connecting with my Judgemates 👩⚖️ Jeff Liter | Chief Executive Officer | OX2 Therapeutics Audrey Greenberg | Co-Founder | Center for Breakthrough Medicines Susan B. Nichols | Chief Executive Officer | Propel Biosciences Bruce Levine | Professor | University of Pennsylvania Nicole K. Paulk, PhD | Founder | Siren Biotechnology Barry Byrne | Director | University of Florida Peter Olagunju | Partner | Catalio Capital Management Amritha J. | Executive Director | IQVIA Troels Jordansen | Founding Partner | Altius Bioventures Stefano Baila | Managing Director | Eurofins Phil Vanek | Chief Technology Officer | Gamma Biosciences Michael E. Meyers | M&A Head | H.C. Wainwrigth & Co Jacqueline Barry | Chief Clinical Officer | Cell and Gene Therapy Catapault Lynn Johnson Langer, PhD, MBA | Consultant | BioPlan Associates Timothy C. Fong | Chief Technology Officer | GenEdit Uma Lakshmipathy | Site Head | Thermo Fisher Scientific 🏆Award Categories🏆 Lifetime Achievement Award Young Scientist Award Simon Ellison Supply Chain Innovation Award Technology Disruptor of the Year CMO/CDMO of the Year Award Cell Therapy Innovator of the Year Award Gene Therapy Innovator of the Year Award Start-up of the Year Award Patient Advocacy Award Leadership & Professional Development Award

Join the most exciting Team in Life Sciences in Minneapolis, MN for Pitch Fest August 13 - 15. #Bullpen Mantra: Find Someone to Help. Repeat. The purpose of Pitch Fest is to gather international life science Bullpen Members, Guests and resources at regional life science hubs to support each other as a community of Dealmakers. There is no single winner - we all win. Request an Invitation: https://lnkd.in/g5p2rX26. Bullpen is an invite-only, volunteer-led Club gathering Life Science Dealmakers with the shared goal of helping each other. Together, we virtually prepare for and attend in-person premier life science events. Bullpen Homepage: https://bullpen.ventures Bullen Mission: https://lnkd.in/gN7rvyZP Bullpen Schedule: https://lnkd.in/gjepJCXB Bullpen Interviews: https://lnkd.in/gaa3sxu5 Become a Member: https://lnkd.in/gKhx6SHN Access Pitch Fest Info Sheet: https://lnkd.in/gXsNWMPH Agenda: 🧢Twins Game🏟️ Focus: Pitch Fest Pre-Party Co-Host: Jess Hawthorne | CSC Leasing Co-Host: TBA ☕️Networking Breakfast🥐 Focus: Industry Associations Co-Host: Roberta Antoine D. | Medical Alley Co-Host: Destination Medical Center (DMC) Leadership TBA Co-Host: MinneAnalytics Leadership TBA Co-Sponsor: TBA 🍔Networking Lunch🍕 Focus: Medical Research Hospital Ventures Co-Host: Mayo Clinic Leadership TBA Co-Host: University of Minnesota Leadership TBA Co-Sponsor: Paula Norbom at Talencio Co-Sponsor: TBA 🍸Networking Happy Hour🍾 Focus: Women-led Host: To Be Announced ⭐️🔥 Co-Sponsor: Caley Anderson, MBA | Collaborative Drug Discovery - CDD Vault Co-Sponsor: TBA 🤘Pitch Rooms💪🏻 Co-Host: Ben Kromnick at Mercury Co-Host: TBA Co-Sponsor: Katie Hjelmstad Severt, MBA at Let's Talk Women 🤓Key Opinion Leader Interviews🧬 Co-Host: James Zanewicz, JD, LLM, RTTP | Tulane University School of Medicine Co-Host: KATRINA ROGERS | Evergreen Bioscience Innovation Cluster Co-Sponsor: Don Davis PhD, MBA at D3 Digital Media Marketing Co-Sponsor: TBA ⚾️Confirmed Pitchers in Comments⚾️ View Attendees: https://lnkd.in/gXsNWMPH 30+ Pitches From: Alabama Boston Chicago Los Angeles Minnesota New Jersey New Orleans Ohio Philadelphia Virginia San Diego San Francisco Toronto United Kingdom Vancouver Washington *Bullpen Club Members Only 👇Host Committee 😘 Jolly Nanda, MBA | CEO | Altheia, Inc. Tom W. Burke | CEO | Vail Scientific, LLC Adam G. Southam | CEO | GoNo Food Finder James Martodam | Independent Medtech Innovator

$𝟮𝟬𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗱𝗲𝗮𝗹𝘀 𝗶𝗻 𝟲 𝗺𝗼𝗻𝘁𝗵𝘀! CGT collabs are leading the way 👇 In H1 2024, strategic collaborations in Cell and Gene Therapy surged and are accounted for as the highest of any therapeutic modality. Nice. Many reasons for this are rapid technological advancements, high therapeutic potential, and the need to share development costs and risks. Regulatory incentives, such as FDA fast tracks + growing demand and IP further drove partnerships. 𝘏𝘦𝘳𝘦’𝘴 𝘸𝘩𝘺 𝘵𝘩𝘪𝘴 𝘪𝘴 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵: 👉 Collaborations are vital as they drive innovation and accelerate development. These partnerships reduce costs and risks, enhance capabilities, and improve efficiency. They also broaden access, navigate regulations, address patient gaps and boost economic growth through job creation as as well as value through demonstrated capabilities for VCs. 𝐓𝐡𝐞 𝐒𝐨𝐮𝐫𝐜𝐞: 𝘛𝘩𝘢𝘯𝘬𝘴 𝘵𝘰 Daniel Parisotto, PhD 𝘈𝘭𝘰𝘯𝘨 𝘸𝘪𝘵𝘩 𝘖𝘱𝘱𝘦𝘯𝘩𝘦𝘪𝘮𝘦𝘳 & 𝘊𝘰 𝘧𝘰𝘳 𝘢𝘭𝘭𝘰𝘸𝘪𝘯𝘨 𝘮𝘦 𝘵𝘰 𝘴𝘩𝘢𝘳𝘦 𝘵𝘩𝘪𝘴. 𝐖𝐡𝐲 𝐝𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐜𝐨𝐥𝐥𝐚𝐛𝐬 𝐡𝐚𝐯𝐞 𝐛𝐞𝐞𝐧 𝐟𝐫𝐞𝐪𝐮𝐞𝐧𝐭 𝐭𝐡𝐢𝐬 𝐲𝐞𝐚𝐫? #celltherapy #genetherapy #biotech #CGTweekly

I am excited to announce that BrainStorm Therapeutics has been awarded a Phase 1 SBIR grant from the National Science Foundation. This funding will support developing and validating a Parkinson’s disease (PD) drug discovery platform utilizing patient-derived midbrain organoid disease models. Traditional drug discovery methods have struggled to produce effective disease-modifying therapies for PD, the second most prevalent neurodegenerative disorder. Annually, more than 90,000 individuals are diagnosed with PD in the US; globally, over 10 million people are affected. The economic burden of PD in the US alone surpasses $52 billion. Our approach will harness familial PD patient-derived midbrain organoid disease models, advanced biomarker-driven screening endpoints, and AI-powered network medicine to identify disease-modifying therapeutics capable of halting, preventing, or reversing dopamine neuron degeneration. We extend our heartfelt thanks to our advisors, mentors, colleagues, friends, and family for their unwavering support as we embark on this worthwhile endeavor. Your guidance and encouragement mean the world to us! @NSF #NSFSBIR #NSFFunded

To all those searching, overcoming, and not giving up - when the road gets tough, remember that resilience, passion, and determination can illuminate your path to greatness. Stay strong and believe in the power within you. Thank you The Medicine Maker for allowing my voice for resilience to be heard. Perhaps it can help someone today to stay strong. #empower IB Communications Likarda Lundmark Advertising.